Physician profile
Rex A Yannis
NPI 1417007691
$19,448.15
in general payments reported to CMS, 2019-2025
19 companies · $205 in 2025
The $205 reported for 2025 was less than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $188 · 2021: $3,327 · 2022: $15K · 2023: $326 · 2024: $307 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $838.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $17,840.20 | 2019-2023 | Tepezza |
| Merz North America, INC. | $437.80 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $378.25 | 2020-2025 | Acthar |
| Amgen INC. | $196.07 | 2024 | Tepezza |
| Allergan, INC. | $93.05 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $59.95 | 2023 | Sotyktu |
| Alcon Vision LLC | $56.99 | 2025 | Tryptyr, Rocklatan |
| Mallinckrodt Enterprises LLC | $54.14 | 2019 | |
| Abbvie INC. | $50.93 | 2024-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $48.56 | 2019 | |
| Ani Pharmaceuticals, INC. | $45.38 | 2025 | Yutiq, Purified Cortrophin Gel |
| Tarsus Pharmaceuticals, INC. | $36.70 | 2024 | Xdemvy |
| Revance Therapeutics, INC. | $31.41 | 2025 | Daxxify |
| Galderma Laboratories, L.P. | $28.39 | 2019-2021 | |
| Biotissue Holdings INC. | $21.66 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Sun Pharmaceutical Industries INC. | $18.16 | 2019 | |
| Dompe US, INC. | $16.63 | 2025 | Oxervate |
| Amarin Pharma, INC. | $14.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rex Yannis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.